Aegis Capital Starts Akers Biosciences (AKER) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts AKER Hot Sheet
Price: $2.47 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Aegis Capital initiated coverage on Akers Biosciences (NASDAQ: AKER) with a Buy rating and a price target of $11.00.
For an analyst ratings summary and ratings history on Akers Biosciences click here. For more ratings news on Akers Biosciences click here.
Shares of Akers Biosciences closed at $4.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Erste Group Starts Nasdaq OMX Group Inc. (NDAQ) at Buy
- CLSA Starts Time Interconnect Technology (1729:HK) at Outperform (2)
- Aletheia Capital Starts Nanometrics (NANO) at Buy, PT $16.90
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
